Bank of Nova Scotia
MRTX

Bank of Nova Scotia’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bank of Nova Scotia’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-72,000
Closed -$4.23M – 1075
2023
Q4 		$4.23M Buy
+72,000
New +$4.05M 0.01% 532
2023
Q2 		– Sell
-99,705
Closed -$3.71M – 1190
2023
Q1 		$3.71M Sell
99,705
-313,628
-76% -$14.1M 0.01% 424
2022
Q4 		$18.7M Buy
413,333
+92,569
+29% +$5.99M 0.05% 248
2022
Q3 		$22.4M Sell
320,764
-520,236
-62% -$38.5M 0.07% 211
2022
Q2 		$56.5M Buy
841,000
+731,000
+665% +$46.5M 0.13% 141
2022
Q1 		$9.04M Buy
110,000
+52,117
+90% +$5.33M 0.02% 471
2021
Q4 		$8.49M Buy
+57,883
New +$8.99M 0.01% 568

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of Nova Scotia's MRTX Position: Q1 2024 in Review

Bank of Nova Scotia sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 72,000 shares — an estimated $4.23M sold.

Bank of Nova Scotia first reported a position in MRTX in Q4 2021 and held it in 7 quarters. The position peaked at $56.5M in Q2 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Bank of Nova Scotia reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Bank of Nova Scotia sold 72,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $4.23M.
  • Bank of Nova Scotia first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Bank of Nova Scotia's Mirati Therapeutics, Inc. Common Stock position peaked at $56.5M in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Bank of Nova Scotia's 13F filing for Q1 2024, filed 15 May 2024.